Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 9%

Bulls say

Arvinas is positioned as a pioneer in the field of targeted protein degradation and has a strong pipeline of clinical and pre-clinical programs in multiple disease areas. With positive biomarker data and a potential first-in-class drug, ARV-102, for Parkinson's disease, the company has a differentiated opportunity in the market. Additionally, Arvinas' partnerships with large pharmaceutical companies provide potential for commercial success and financial stability. With a robust cash position and a strong portfolio, Arvinas is well-positioned for future growth and success, making it an attractive investment opportunity.

Bears say

Arvinas is facing challenges in hematology and a competitive biotech market, leading to lower expectations in their clinical-stage product candidates. The recent data on their LRRK2 degrader, ARV-102, demonstrated decent results but is not expected to receive approval until 2026, and the stock reflects the challenges rather than the specific data. The company has a strong potential with their BCL6 degrader, ARV-393, and a potential partnership for ex-US commercialization, but the stock currently reflects the delayed timeline for potential approval and the uncertainties in their other therapeutics.

Arvinas Inc (ARVN) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 11 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.